SiRNA for improving developmental capacity of cryopreserved oocytes and application thereof
By inhibiting the expression of the Atf5 gene of the Atf5 gene, the problem of abnormal mitochondrial function of frozen oocytes is solved, and the development ability and tolerance of frozen oocytes are significantly improved.
Patent Information
- Application Number
- CN202411121109.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-15
AI Technical Summary
The developmental ability of frozen oocytes decreases after thawing, and abnormal mitochondrial function is the main limiting factor restricting the application of frozen oocytes, especially in the condition of frozen stress, mitochondrial function is difficult to maintain.
A siRNA molecule that inhibits the expression of Atf5 gene was designed to silence the Atf5 gene of oocytes through RNA interference technology, thereby maintaining mitochondrial function and improving the development ability of frozen oocytes.
By inhibiting Atf5 gene expression, the expression of Atf5 in frozen oocytes is significantly reduced, mitochondrial function is maintained, and the development ability and tolerance of frozen oocytes are improved.
Smart Images

Figure CN119020360A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of ultra-low temperature cryopreservation of oocytes, and in particular relates to siRNA for improving the developmental ability of frozen oocytes and application thereof. Background Art
[0002] Oocyte cryopreservation is a basic means of preserving fertility and plays an important role in assisted reproductive technology. Although oocyte cryopreservation technology has made great progress, the developmental capacity of frozen oocytes decreases after thawing, and low freezing efficiency has become the main limiting factor for the application of frozen oocytes. Mitochondrial function is the guarantee of normal development of oocytes, and mitochondria are extremely sensitive to changes in temperature and osmotic pressure during freezing and thawing. Studies have shown that the mitochondrial morphology and spatial distribution in frozen oocytes are abnormal, and freezing can induce mitochondrial dysfunction. Given the key role of mitochondria in oocyte development, maintaining mitochondrial function can improve the developmental capacity of frozen oocytes.
[0003] The mitochondrial unfolded protein response (mtUPR) is the main response mechanism of mitochondria to external environmental stimuli. The mitochondrial molecular chaperone heat shock protein 60 (Hsp60) is a biomarker of mtUPR and plays a key role in maintaining mitochondrial function. Activating transcription factor 5 (Atf5) is a key regulator of mammalian mtUPR. Studies have shown that Atf5 is necessary for the recovery of organelles after mitochondrial stress in mammalian cells. At present, the effect of Atf5 on mitochondrial function and developmental capacity of frozen oocytes is still unknown.
[0004] RNA interference (RNAi) is an effective method for regulating target gene expression, which can efficiently and specifically inhibit target mRNA expression. Exogenous small interfering RNA (siRNA) is the main RNAi molecule, which can induce the formation of silencing complexes to achieve post-transcriptional gene regulation. RNAi has been proven to be an adaptable and powerful therapeutic strategy. A variety of siRNA drugs have been approved, and several RNAi-based treatments are also advancing clinical trials. However, there are no reports on the use of siRNA targeting Atf5 to improve the developmental capacity of frozen oocytes. Summary of the invention
[0005] In order to solve the above technical problems, the present invention proposes siRNA and its application for improving the developmental ability of frozen oocytes, discovers a siRNA molecule that inhibits the expression of Atf5 gene, and evaluates its effect on the developmental ability of frozen oocytes, in order to maintain mitochondrial function under freezing stress conditions and improve the developmental ability of frozen oocytes.
[0006] To achieve the above object, the present invention provides siRNA molecules for improving the developmental ability of frozen oocytes. The nucleotide sequences of the siRNA molecules are shown in SEQ ID NO.1 and SEQ ID NO.2.
[0007] The present invention also provides the use of the siRNA molecule in preparing a preparation for improving the developmental ability of cryopreserved oocytes.
[0008] Preferably, the cryopreservation is ultra-low temperature cryopreservation at -196°C.
[0009] Preferably, the siRNA molecule inhibits the expression of Atf5 gene, thereby maintaining mitochondrial function and improving the developmental capacity of cryopreserved oocytes.
[0010] Further preferably, the nucleotide sequence of the Atf5 gene is as shown in SEQ ID NO.3.
[0011] The present invention also provides a preparation for improving the developmental ability of frozen oocytes, comprising the siRNA molecule.
[0012] Preferably, the preparation further comprises a pharmaceutically acceptable excipient.
[0013] Preferably, the preparation is an injection.
[0014] The present invention also provides a nucleic acid construct for improving the developmental ability of frozen oocytes, wherein the nucleic acid construct comprises the siRNA molecule.
[0015] The present invention also provides a method for improving the developmental ability of frozen oocytes, comprising the following steps: after obtaining the oocytes, injecting the siRNA molecules, and then freezing and preserving them.
[0016] Compared with the prior art, the present invention has the following advantages and technical effects:
[0017] The present invention uses mouse oocytes as a model, and silences the oocyte Atf5 gene by RNA interference, thereby maintaining mitochondrial function under freezing stress environment, enhancing oocyte freezing tolerance, and improving frozen oocyte development ability. Provided is a siRNA that targets and inhibits Atf5 gene expression, and the nucleotide sequence is shown in SEQ ID NO.1 and SEQ ID NO.2. The siRNA is used in oocyte freezing, and the siRNA is microinjected into the oocyte cytoplasm. The siRNA can specifically silence the target gene mRNA expression. The results show that the expression of the oocyte Atf5 gene is significantly reduced after the injection of siRNA, the mitochondrial function is maintained under freezing stress, and the frozen oocyte development ability is improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0019] Figure 1 To measure the effect of freezing on the developmental capacity of oocytes, A is a representative picture of GVBD and PBE of fresh and frozen oocytes, with a scale of 100 μm, and B is a ratio analysis of GVBD and PBE of fresh and frozen oocytes;
[0020] Figure 2 To determine the effect of freezing on oocyte mitochondrial function, A is TMRM fluorescence staining to detect mitochondrial membrane potential of fresh and frozen oocytes, the scale bar is 100μm, B is TMRM fluorescence intensity analysis of fresh and frozen oocytes, C is 2'7'-DCFHDH fluorescence staining to detect ROS levels in fresh and frozen oocytes, the scale bar is 100μm, D is 2'7'-DCFHDH fluorescence intensity analysis of fresh and frozen oocytes, E is ATP content detection of fresh and frozen oocytes;
[0021] Figure 3 To determine the effect of freezing on the expression of ATF5 and HSP60 in oocytes, A is the immunofluorescence staining picture of ATF5 in fresh and frozen oocytes, the scale bar is 100μm, B is the immunofluorescence staining picture of HSP60 in fresh and frozen oocytes, the scale bar is 50μm, C is the fluorescence intensity analysis of ATF5 in fresh and frozen oocytes, and D is the fluorescence intensity analysis of HSP60 in fresh and frozen oocytes;
[0022] Figure 4 The effect of low expression of Atf5 on the developmental ability of frozen oocytes was determined, where A shows that injection of siRNA can reduce the expression of Atf5 in oocytes, B shows the representative pictures of GVBD and PBE of frozen and siAtf5 frozen oocytes, with a scale of 100 μm, and C shows the ratio analysis of GVBD and PBE of frozen and siAtf5 frozen oocytes;
[0023] Figure 5 The effect of low expression of Atf5 on the mitochondrial function of frozen oocytes was determined, where A is the TMRM fluorescence staining to detect the mitochondrial membrane potential of frozen and siAtf5 frozen oocytes, the scale bar is 100μm, B is the TMRM fluorescence intensity analysis of frozen and siAtf5 frozen oocytes, and C is the expression analysis of genes related to mitochondrial dynamics in frozen and siAtf5 frozen oocytes;
[0024] Figure 6 The effect of low expression of Atf5 on the mitochondrial function of fresh oocytes was determined, where A is the TMRM fluorescence staining to detect the mitochondrial membrane potential of fresh and siAtf5 fresh oocytes, with a scale of 100 μm; B is the TMRM fluorescence intensity analysis of fresh and siAtf5 fresh oocytes; C is the ATP content analysis of fresh and siAtf5 fresh oocytes; and D is the expression analysis of genes related to mitochondrial dynamics in fresh and siAtf5 fresh oocytes. DETAILED DESCRIPTION
[0025] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0026] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0027] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0028] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to the skilled artisan. The present invention description and examples are exemplary only.
[0029] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0030] Example 1
[0031] Analysis of Atf5 gene expression in cryopreserved oocytes
[0032] 1. Oocyte Acquisition
[0033] Female 6-week-old ICR mice were purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd. The mice were maintained in a 12-h dark / 12-h light cycle and allowed to eat and drink freely. They were used for experiments after a one-week adaptation period. The mice were intraperitoneally injected with 10 IU pregnant mare serum gonadotropin (PMSG). After 48 hours, the mice were killed by cervical dislocation. The ovaries were removed and placed in HX-M199 solution pre-equilibrated for 4 hours, and shaken to rinse to clean excess impurities. The ovaries were then transferred to a clean culture dish, and the ovaries were fully minced using a sterile blade to release the contents of the follicles. Then, pre-equilibrated HX-M199 solution was added, and the cumulus-oocyte complexes (COCs) were collected into new pre-equilibrated HX-M199 solution using a mouth pipette. COCs were blown and sucked with a mouth pipette slightly larger than the diameter of the oocyte to completely detach the granulosa cells.
[0034] 2. Oocyte freezing and thawing
[0035] Freezing method: First, the oocytes were equilibrated in a pretreatment solution (10% EG (v / v) + 10% DMSO (v / v)) for 30 seconds, and then transferred to a vitrification solution (Dulbecco's phosphate-buffered saline medium (DPBS) containing 0.5 M sucrose, 30% Ficoll (w / v), 15% EG (v / v) and 15% DMSO (v / v)), kept for 25 seconds, and sucked into the tip of OPS, and then the OPS containing the oocytes was quickly immersed in liquid nitrogen for storage (-196°C).
[0036] Thawing method: Take out the OPS straw from liquid nitrogen and quickly immerse it in thawing medium (DPBS containing 0.5 M sucrose) for 5 min.
[0037] 3. Oocyte Maturation in vitro
[0038] Oocytes were washed three times in IVM medium (Cat. M7292, Sigma) and subjected to IVM culture. After 2 h or 12 h of IVM culture, the GVBD rate and PBE rate were recorded, respectively.
[0039] 4. Mitochondrial membrane potential detection
[0040] Mitochondrial membrane potential was measured using TMRM fluorescent probe (Cat.I34361, Invitrogen). The oocytes were stained for 30 min at 37 °C with 100 nM TMRM working solution diluted with M2 medium containing milrinone. After washing three times with M2 medium containing milrinone, images were taken using an Olympus IX71 inverted fluorescence microscope. EZ-C1 FreeViewer software measured the fluorescence intensity and determined the average fluorescence intensity per unit area within the ROI to quantify the fluorescence of a single oocyte image.
[0041] 5. Detection of reactive oxygen species (ROS) levels
[0042] ROS levels were measured using the fluorescent probe 2', 7'-dichlorofluorescein diacetate (DCFHDA; Cat. D399, Invitrogen). The oocytes were stained at 37°C for 30 min after dilution with milrinone-containing M2 medium to 1 mM 2', 7'DCFHDA working solution. After washing three times with milrinone-containing M2 medium, images were taken using an Olympus IX71 inverted fluorescence microscope. Fluorescence intensity was measured using EZ-C1 FreeViewer software, and the average fluorescence intensity per unit area within the ROI was determined to quantify the fluorescence of a single oocyte image.
[0043] 6. ATP level detection
[0044] ATP levels were measured using an enhanced ATP assay kit (Cat. S0027, Beyotime). Transfer each group of oocytes (10 oocytes per sample) to 50 μL of lysis buffer and vortex to lyse the cells. Add ATP assay working solution (50 μL / well) to a new 96-well plate and let stand at room temperature for 5 min. Set up 5 standard wells and add standard samples (0 μL, 2 μL, 4 μL, 8 μL, 16 μL) to the 96-well plate. Then, adjust the volume to 50 μL with lysis buffer. For the sample wells, add 50 μL of sample lysis buffer. ATP levels were determined using an Infinite F200 microplate reader.
[0045] 7. Immunofluorescence staining
[0046] GV stage oocytes were fixed in immunofluorescence staining fixation solution (Cat. P0098, Beyotime) for 30 min at room temperature, permeabilized with PBS solution containing 0.1% TritonX-100 and 0.1% PVA for 1 h at room temperature, and blocked in blocking solution (PBS solution containing 3% BSA, 0.1% TritonX100, 0.1% PVA) for 1 h at room temperature, and then incubated with anti-Atf5 (1:200, Cat. AF2563, Beyotime) and anti-HSP60 (1:200, Cat. bs-0191R, Bioss) antibodies overnight at 4°C. Images were captured and analyzed using a Nikon A1 confocal microscope.
[0047] 8. Data Analysis
[0048] All statistical analyses were performed using GraphPad Prism 8 software. Independent t-test and chi-square test were used to evaluate the differences between the two groups. All experiments were repeated at least three times, and the results are presented as mean ± SEM. When P < 0.05, it was considered statistically significant.
[0049] result
[0050] 1. Freezing can lead to a decrease in the developmental capacity of oocytes
[0051] Representative images of GVBD and PBE in in vitro maturation of fresh and frozen oocytes Figure 1 As shown in Figure A, statistical analysis showed that freezing could cause a significant decrease in the proportion of oocyte GVBD (80.64±2.15 vs 71.80±2.21, P<0.05) and PBE (90.74±2.32 vs 68.86±7.93, P<0.05) (e.g. Figure 1 (B).
[0052] 2. Cryopreservation can cause mitochondrial dysfunction in oocytes
[0053] Mitochondrial membrane potential detection in fresh and frozen oocytes Figure 2 As shown in A. Compared with the fresh group, the mitochondrial membrane potential of frozen oocytes decreased significantly (9838.00±205.90vs8350.00±162.50, P<0.01, as shown in Figure 2 As shown in B). Figure 2 As shown in C, 2'7'-DCFHDH fluorescence staining was used to detect the ROS level in oocytes. The ROS level in frozen oocytes was significantly higher than that in fresh oocytes (9690.00±111.90vs10567.00±245.20, P<0.01, as shown in Figure 2 In addition, the ATP level in frozen oocytes was significantly decreased (1.20±0.02 vs 1.01±0.02, P<0.01, as shown in Figure 5D). Figure 2 (shown in E).
[0054] 3. Freezing can cause abnormal increase in ATF5 levels
[0055] Immunofluorescence staining was used to detect the expression of ATF5 protein in oocytes (eg Figure 3 The results showed that the expression of ATF5 in frozen oocytes was significantly increased (152.40±10.34 vs 416.40±53.08, P<0.01). Figure 3 The expression of HSP60, a biomarker of mtUPR, was further detected (as shown in Figure 2B). Figure 3C), immunofluorescence staining results showed that the expression of HSP60 in the frozen group was significantly higher than that in the fresh group (543.90±22.54 vs 669.10±27.24, P<0.01, as shown in Figure 5C). Figure 3 (shown in D).
[0056] Example 2
[0057] Low expression of Atf5 can improve the developmental capacity of cryopreserved oocytes
[0058] The methods for obtaining oocytes, freezing and thawing, in vitro maturation, and mitochondrial membrane potential detection are the same as those in Example 1. The difference from Example 1 is that after the oocytes are obtained, siRNA that inhibits the expression of Atf5 is microinjected to construct oocytes with low expression of Atf5, and the changes in mitochondrial functional parameters such as mitochondrial dynamics after freezing are evaluated. The specific scheme is as follows:
[0059] 1. siRNA sequence
[0060]
[0061] According to the Atf5 nucleotide sequence, three pairs of siRNA were designed, and the negative control siRNA was used as a control. All siRNA sequences are shown in Table 1 below:
[0062] Table 1 siRNA sequences
[0063] Gene Sequence (5'-3') Serial number NC-siRNA-F UUCUCCGAACGUGUCACGUTT SEQ ID NO.4 NC-siRNA-R ACGUGACACGUUCGGAGAATT SEQ ID NO.5 Atf5-siRNA#722-F GCCCUUGCCCACCUUUGACTT SEQ ID NO.1 Atf5-siRNA#722-R GUCAAAGGUGGGCAAGGGCTT SEQ ID NO.2 Atf5-siRNA#820-F GCUUGUCAACCCUGCCUGUTT SEQ ID NO.6 Atf5-siRNA#820-R ACAGGCAGGGUUGACAAGCTT SEQ ID NO.7 Atf5-siRNA#964-F UCAGGUACCGCCAGAGGAATT SEQ ID NO.8 Atf5-siRNA#964-R UUCCUCUGGCGGUACCUGATT SEQ ID NO.9
[0064] 2. siRNA Microinjection
[0065] The siRNA was diluted to 20 μM, and about 10 pL of siRNA was injected into the cytoplasm of GV stage oocytes using FemtoJet4i microinjector (Eppendorf). The injected oocytes were cultured in M2 solution containing 2.5 μM milrinone in an incubator at 37°C and 5% CO2 for 24 h. The V_NC group and V_si group represent oocytes injected with negative siRNA and Atf5 siRNA sequences, respectively.
[0066] 3. Mitochondrial dynamics gene expression detection
[0067] RNA was extracted using TRIzol chloroform extraction and PrimeScript TM RT Master Mix (Perfect RealTime; Cat.RR036A, Takara) was used to reverse transcribe into cDNA. The efficiency of the primers was tested to ensure their specificity. Tip Green qPCR SuperMix (+ Dye II) (Cat. AQ142-22, Transgen) Instructions Prepare the reaction system and perform qRT-PCR using the ABI 7500 qRT-PCR system (Applied Biosystems). -△△Ct The method was used to calculate the relative expression levels of target genes, and Ppia and Rpl7 were used as internal reference genes. Table 2 lists all primer sequences.
[0068] Table 2 Primer sequences
[0069]
[0070]
[0071] result
[0072] 1. Low expression of Atf5 can improve the developmental capacity of frozen oocytes
[0073] like Figure 4As shown in Figure A, microinjection of Atf5 siRNA can significantly reduce the expression of Atf5 in oocytes, among which the microinjection of siRNA molecules Atf5-siRNA#722-F (SEQ ID NO.1) and Atf5-siRNA#722-R (SEQ ID NO.2) groups most significantly reduced the expression of Atf5 in oocytes. The development of frozen oocytes in the negative control group (V_NC) and the selected siRNA molecules Atf5-siRNA#722-F (SEQ ID NO.1) and Atf5-siRNA#722-R (SEQ ID NO.2) injection group (V_si) is shown in Figure A. Figure 4 As shown in B, the GVBD ratio of frozen oocytes in the V_si group was significantly increased (60.02±1.73 vs 68.52±1.91, P<0.05, as shown in Figure 4 The PBE ratio is also improved to a certain extent.
[0074] 2. Low expression of Atf5 can improve mitochondrial function in frozen oocytes
[0075] The mitochondrial membrane potential of two groups of frozen oocytes was measured ( Figure 5 The results showed that the mitochondrial membrane potential of frozen oocytes in the siRNA molecule Atf5-siRNA#722-F (SEQ ID NO.1) and Atf5-siRNA#722-R (SEQ ID NO.2) injection groups was significantly increased (6655.00±204.40vs7463.00±268.20, P<0.05, as shown in Figure 2A). Figure 5 Further analysis revealed that the expression of mitochondrial dynamics-related genes (Drp1, Opa1) in the V_si group was significantly increased compared with the V_NC group (as shown in Figure 2B). Figure 5 (as shown in C).
[0076] Example 3
[0077] Low expression of Atf5 is closely related to mitochondrial function in fresh oocytes
[0078] The methods for obtaining oocytes, in vitro maturation, mitochondrial membrane potential, and ATP content detection were the same as in Example 1. siRNA molecules Atf5-siRNA#722-F (SEQ ID NO.1) and Atf5-siRNA#722-R (SEQ ID NO.2) were selected, and oocytes with low expression of Atf5 were constructed by microinjection. The method for expressing genes related to mitochondrial dynamics was the same as in Example 2 to evaluate the effect of low expression of Atf5 on mitochondrial function of fresh oocytes.
[0079] result
[0080] TMRM staining was used to detect the mitochondrial membrane potential (MMP) of oocytes in the fresh negative control group (F_NC) and the siRNA molecules Atf5-siRNA#722-F (SEQ ID NO.1) and Atf5-siRNA#722-R (SEQ ID NO.2) injection groups (F_si). Figure 6 As shown in Figure 2A, the mitochondrial membrane potential of the F_si group was significantly decreased compared with that of the F_NC group (7410.00±217.20 vs 6664.00±230.50, P<0.05). Figure 6 As shown in B), and as Figure 6 As shown in C, the ATP level in the F_si group was significantly reduced (0.98±0.01 vs 0.85±0.04, P<0.01). The expression of genes related to mitochondrial dynamics in oocytes of the two groups was further detected. The results showed that the expression of Drp1, Fis-1, Opa1, Mfn1, and Mfn2 in oocytes of the F_si group was significantly reduced (as shown in Figure 6 (middle D).
[0081] In summary, the above results indicate that increased levels of Atf5 in frozen oocytes are associated with abnormal mitochondrial function and decreased oocyte developmental ability. Using the siRNA method, siRNA molecules Atf5-siRNA#722-F (SEQ ID NO.1) and Atf5-siRNA#722-R (SEQ ID NO.2) were prepared, which can effectively inhibit the expression of Atf5, thereby specifically maintaining the mitochondrial function of frozen oocytes and thereby improving the developmental ability of frozen oocytes.
[0082] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. An siRNA molecule for improving the developmental ability of frozen oocytes, characterized in that: The nucleotide sequences of the siRNA molecules are shown in SEQ ID NO.1 and SEQ ID NO.
2.
2. Use of the siRNA molecule as claimed in claim 1 in the preparation of a preparation for improving the developmental ability of cryopreserved oocytes.
3. The application according to claim 2, characterized in that: The cryopreservation is -196°C ultra-low temperature cryopreservation.
4. The application according to claim 2, characterized in that: The siRNA molecule inhibits the expression of the Atf5 gene, thereby maintaining mitochondrial function and improving the developmental capacity of cryopreserved oocytes.
5. The application according to claim 4, characterized in that: The nucleotide sequence of the Atf5 gene is shown in SEQ ID NO.
3.
6. A preparation for improving the developmental ability of frozen oocytes, characterized in that: Comprising the siRNA molecule according to claim 1.
7. The preparation according to claim 6, characterized in that The preparation also includes pharmaceutically acceptable excipients.
8. The preparation according to claim 6, characterized in that The preparation is an injection.
9. A nucleic acid construct for improving the developmental ability of frozen oocytes, characterized in that: The nucleic acid construct comprises the siRNA molecule according to claim 1.
10. A method for improving the developmental capacity of frozen oocytes, characterized in that: The following steps are involved: After obtaining the oocyte, the siRNA molecule of claim 1 is injected and then cryopreserved.
Citation Information
Patent Citations
Method for efficiently protecting mitochondrial function of vitrified frozen bovine oocyte
CN104886040A
Method for completely silencing target gene of embryo by improving microinjection of siRNA
CN107858377A
Small interfering RNA targeting ATF5 and application thereof
CN112877328A
Oocyte cryopreservation reagent and application thereof
CN114847274A
Methods for regulating the growth and / or survival of tumor cells and stem cells by modulating the expression or function of the transcription factor ATF5
US20060088934A1
Cited By
SiRNA molecule for inhibiting Rab11fip4 gene and application
CN120099008A
